about
Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patientsSterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in MiceSurgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis.Evaluation of data quality in a laboratory-based surveillance of M. tuberculosis drug resistance and impact on the prevalence of resistance: France, 2004.Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.Activities of several antimicrobials against Mycobacterium ulcerans infection in mice.Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice.Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice.Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in miceIn vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.Comparison of nine phenotypic methods for detection of extended-spectrum beta-lactamase production by Enterobacteriaceae.Different factors associated with CTX-M-producing ST131 and non-ST131 Escherichia coli clinical isolatesMolecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis.First multicenter study on multidrug resistant bacteria carriage in Chinese ICUs.Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratoryBactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in miceImpacts of dosing frequency of the combination rifampin-streptomycin on its bactericidal and sterilizing activities against Mycobacterium ulcerans in miceRapid curbing of a vancomycin-resistant Enterococcus faecium outbreak in a nephrology department.Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis.Carbapenem use in French hospitals: A nationwide survey at the patient level.Multidrug and extensively drug-resistant tuberculosis.Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests.Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in community-onset urinary tract infections in France in 2013.Impact of the BCG vaccination policy on tuberculous meningitis in children under 6 years in metropolitan France between 2000 and 2011.Application of guidelines for aminoglycosides use in French hospitals in 2013-2014.Multidrug-resistant bacteria transmitted through high-density EEG in ICU.XDR-tuberculosis in France: Community transmission due to non-compliance with isolation precautions.Survey of French physician practices in treatment and control of transmission of smear-positive tuberculosis.Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacterium intracellulare.Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex.A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union.Multidrug-resistant tuberculosis: eight years of surveillance in France.Decrease in the incidence of culture-positive meningitis and cerebral tuberculomas in France from 1990 to 2007.Molecular epidemiology of OXA-48-producing Klebsiella pneumoniae in France.qnrA6 genetic environment and quinolone resistance conferred on Proteus mirabilis.[Resistance to antituberculous drugs]Assessment of organizational measures to prevent nosocomial tuberculosis in health facilities of 4 sub-Saharan countries in 2010.Incidence rates of carbapenemase-producing Enterobacteriaceae clinical isolates in France: a prospective nationwide study in 2011-12.
P50
Q28482730-8B0AD801-D52E-4AAF-8A04-6C5A07873211Q28552736-F70AF5B3-9E44-4308-8088-A2A19374663FQ31036451-4F64271C-D4C1-4661-8330-CBE464EBFB10Q31137273-30A06557-9E39-4AEA-887F-C2D3BB647D83Q33975861-06DF7044-C66B-47C5-8956-55C8CE203628Q33980444-AA138465-1AA1-4B67-90F1-E55A10ACF0B7Q33983346-4B6955C6-8932-4175-85B3-816F778A132EQ33983428-942B9A1B-9459-446B-BF88-AABE951806AAQ34144367-4B2C5FB8-BB3E-478F-9DC5-8909016C22A6Q34680628-1DF69FE0-F021-4E7C-9928-1353F3AF36BCQ34741114-547FC1FB-A1FC-420B-87CF-3B0B343FC7B3Q34983886-107A20B4-941C-4A81-BA65-709EB5F350D9Q35076978-0D438CD3-DBD2-425D-97C9-F17E5B672F86Q35750812-9CC2B8F9-FEF2-48BE-B32D-F35B0C61AD83Q36251716-D633224B-2CEE-42EC-98DE-BB93C361FC40Q36703065-B68D3CD2-67B9-475B-AA2B-842670B44D19Q37247677-71466355-B116-4A9D-B334-017ADF595E9BQ37378430-0E7860A7-882D-4537-8421-0213B0114C27Q37502309-5A422016-CC6D-4CEC-A0CF-F62F84101D29Q38949146-13A43B12-EFF9-4A81-89D8-ADF8A13FD4FDQ38956830-47BDA989-75E4-4779-B788-A7849FEED5E7Q38969662-5BA5C7B1-E9BF-4CC2-8589-6FFCF9AE8391Q39412049-3FB6F7E3-BD58-4455-A8C6-EF2CFE43C035Q40172748-28E4B255-D439-4DE0-9369-8F46E26FCFDEQ40266513-A9FE0B2E-42D6-4039-BB69-F8B77C5024FAQ40378234-0DF7EBE2-2B6A-44B7-94DF-EBC7E43D345DQ40737378-AB7021E5-2A5E-4E93-AD03-BBAA30861C3BQ40818642-01EDC8D0-F6EF-426A-A932-852DC3BC490BQ41553099-B6ECC429-2A14-4301-AD29-E2CDF7462942Q41699273-8BB0D5FC-76A8-48FE-ACED-3147D7A1C0F1Q43126100-1AE426CB-DCEF-4608-A505-BC0B7E5F3746Q43223526-9D13FDC7-1A76-459A-B84D-79341331461AQ43926052-7356CB51-A38B-4FA9-A6D7-B9E705786916Q44657665-23EAC544-79A1-4421-845A-9A591FA10C0DQ45245023-D9739B29-C38B-47E1-A062-28578DB8EBB7Q45267845-2AE6E65A-21FC-41EC-88D1-ACB7DB67FE95Q46613232-142AC2A1-0806-4001-9D93-FE9AA612BAB9Q46675445-9AE6C074-EFB5-4D41-B2D6-5399E6332B24Q46864484-703C7507-ACD7-45B6-AE75-D157E2BF4AF0Q46877738-05B17D26-9490-4338-BD97-7185A625B973
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jerome Robert
@ast
Jerome Robert
@en
Jerome Robert
@es
Jerome Robert
@nl
type
label
Jerome Robert
@ast
Jerome Robert
@en
Jerome Robert
@es
Jerome Robert
@nl
prefLabel
Jerome Robert
@ast
Jerome Robert
@en
Jerome Robert
@es
Jerome Robert
@nl
P106
P31
P496
0000-0002-9380-0570